Intel Stock Plunges: Time To Buy the Dip?

Intel reported Q4 revenue of $13.7 billion, down 4% year-over-year but ahead of consensus ($13.4 billion); adjusted operating income fell to $1.21 billion from $1.37 billion while adjusted EPS rose to $0.15 (vs. $0.13 prior year) and beat expectations of $0.08. Management warned that supply constraints will depress Q1 supply, guiding revenue of $11.7–$12.7 billion (midpoint down ~4.7% YoY) and break-even adjusted EPS versus a $0.05 consensus and $0.13 a year ago. The weak Q1 outlook sent the stock down ~16% intraday, underscoring a gap between elevated market expectations for Intel's turnaround (supported by recent government and Nvidia investments) and near-term operational/headcount constraints that analysts expect will keep growth in the single digits through 2027.

Analysis

Market structure: Intel's guidance and supply constraints are a near-term win for AI-focused incumbents (NVDA) and pure-play foundries that can take share during Q1 (higher-priced constrained nodes). Hyperscalers face short-term sourcing risk, which raises bargaining power for alternative suppliers and could pressure Intel's ASP mix; consensus single-digit revenue growth to 2027 implies expectations are front-loaded into INTC's premium multiple.

Risk assessment: Tail risks include failed 18A ramp (yield shortfalls) triggering >10%-20% equity dilution within 12-24 months, or an adverse CHIPS funding delay that removes a structural backstop; operational supply disruptions in Q1 could deepen revenue misses. Time horizons: immediate (days) for volatility and guidance reaction, short-term (Q1–Q2) for supply normalization, long-term (18–36 months) for foundry/18A payoff; hidden risk—deconsolidation (Alterra) masks comparability and cash-flow strength.

Trade implications: Near term, protect/short INTC vs long NVDA exposure — NVDA retains secular AI tailwinds and optionality from its existing business; use defined-risk options to express views and limit capital at risk. Sector action: rotate incrementally into AI infrastructure names and underweight legacy CPU-exposed suppliers until Q2 yields and CHIPS milestones are confirmed.

Contrarian: The market may be underpricing a Q2 supply rebound — if Intel confirms “improving supply” on the Q2 call, a reflexive squeeze of 20–40% intra-12 months is plausible given the premium already paid for turnaround optionality. Conversely, if 18A yield transparency is delayed beyond H2 2026, downside could exceed current drawdowns; position sizing should reflect this binary outcome.

Key Decisions for Investors

• Establish a 1–2% portfolio-sized, defined-risk hedge: buy a 30–45 day INTC put spread sized to pay off if INTC declines >15% from current levels (buy ~10% OTM put, sell ~20% OTM put), reassess after the Q1 call (action window: next 7 trading days).
• Implement a 0.5–1% long in NVDA funded by a 1–2% short or reduced long in INTC (pair trade: long NVDA, short INTC) for a 3-month tactical trade; target relative outperformance of NVDA vs INTC by 15–25% over 3 months, cut losses if pair moves against by 8% absolute.
• If INTC falls another ~20% from current levels, deploy 2–3% of portfolio into long-dated upside: buy Jan 2028 LEAP calls ~40–50% OTM (speculative turnaround ticket) with max loss = premium; reassess after Q2 supply commentary and 18A yield updates.
• Overweight AI infrastructure by +1–2% (increase NVDA and GPU ecosystem exposure) and reduce exposure to legacy CPU/PC cyclicals by -1–2% through the next 6 months; re-evaluate after CHIPS Act funding milestones and Q2 supply statements.
• Monitor specific catalysts over the next 90 days: Q1 revenue vs guidance midpoint, commentary that ‘available supply’ improves in Q2, public 18A yield metrics, and CHIPS disbursement timing — take profits or cut positions if Q2 supply is not confirmed on the Q1 earnings call.